Healthcare Global Enterprises sees strong financial growth, strategic expansion

For the fiscal year ended March 31, 2025, Healthcare Global Enterprises Limited reported consolidated income from operations, including government grants, of INR 22,228.50 million, a 16.25% increase from the previous fiscal year. Consolidated EBITDA rose by 22% to INR 3,872.84 million, with a sustained margin of 17.42%. Standalone income from operations also grew by 9.04% to INR 12,804.89 million, and profit after tax stood at INR 444.10 million for the consolidated entity.

Strategic initiatives included the acquisition of a 51% equity stake in Vizag Hospital And Cancer Research Centre Private Limited for INR 2,076 million, with plans to acquire an additional 34% within 18 months. HCG also approved the acquisition of the oncology business located at Nagpur for a consideration not exceeding INR 25 Crores and the transfer of its diagnostic business to HCG NCHRI Oncology LLP for up to INR 135 Crores. These moves aim to enhance market positioning and operational efficiency.

The company will hold its 27th Annual General Meeting on September 25, 2025, via video conferencing. HCG emphasized its focus on high-quality, tech-enabled cancer care, delivering advanced therapies across its network, and commitment to sustainable growth with disciplined capital allocation.